Evolus Inc (EOLS)

Dec 20, 2024

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability - Yahoo Finance

Dec 20, 2024

Dec 16, 2024

Lord Abbett & CO. LLC Acquires 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Dec 16, 2024

Dec 16, 2024

Stock Options Galore! Discover Evolus’ Latest Move - Jomfruland.net

Dec 16, 2024

Dec 14, 2024

(EOLS) On The My Stocks Page - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Evolus Expands Team with Strategic Equity Incentives Package for 20 New Hires - StockTitan

Dec 13, 2024

Dec 13, 2024

Evolus's SWOT analysis: aesthetics firm's stock poised for growth By Investing.com - Investing.com South Africa

Dec 13, 2024

Dec 13, 2024

Evolus's SWOT analysis: aesthetics firm's stock poised for growth - Investing.com

Dec 13, 2024

Dec 12, 2024

Charles Schwab Investment Management Inc. Buys 265,635 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Dec 12, 2024

Dec 05, 2024

Evolus, Inc. (NASDAQ:EOLS) Is Expected To Breakeven In The Near Future - Simply Wall St

Dec 05, 2024

Dec 03, 2024

212,209 Shares in Evolus, Inc. (NASDAQ:EOLS) Acquired by Walleye Capital LLC - MarketBeat

Dec 03, 2024

Nov 28, 2024

Connor Clark & Lunn Investment Management Ltd. Takes $940,000 Position in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Nov 28, 2024

Nov 27, 2024

Great Point Partners LLC Has $18.95 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Nov 27, 2024

Nov 23, 2024

Jeffrey Plumer: Defending a ‘Whole New World’ - Orange County Business Journal

Nov 23, 2024

Nov 22, 2024

When (EOLS) Moves Investors should Listen - Stock Traders Daily

Nov 22, 2024

Nov 20, 2024

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher - MSN

Nov 20, 2024

Nov 18, 2024

Evolus, Inc. (NASDAQ:EOLS) Short Interest Up 8.8% in October - MarketBeat

Nov 18, 2024

Nov 17, 2024

OC500 2024: Sandra Beaver - Orange County Business Journal

Nov 17, 2024

Nov 15, 2024

Behind the Bell: Evolus - Nasdaq

Nov 15, 2024

Nov 15, 2024

Perceptive Advisors LLC Adjusts Stake in Evolus Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Stonepine Capital Management Reduces Stake in Evolus Inc - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26% - Simply Wall St

Nov 13, 2024

Nov 13, 2024

Evolus, Inc. (NASDAQ:EOLS) Position Increased by GSA Capital Partners LLP - MarketBeat

Nov 13, 2024

Nov 12, 2024

Evolus Inc (EOLS) Shares Gap Down to $12.58 on Nov 12 - GuruFocus.com

Nov 12, 2024

Nov 11, 2024

Evolus Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 11, 2024

Nov 11, 2024

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 11, 2024

Nov 09, 2024

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 08, 2024

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges By GuruFocus - Investing.com Canada

Nov 08, 2024

Nov 07, 2024

Evolus (NASDAQ:EOLS) Shares Gap Down on Disappointing Earnings - MarketBeat

Nov 07, 2024

Nov 07, 2024

Evolus' (EOLS) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 07, 2024

Nov 07, 2024

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Evolus earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada

Nov 07, 2024

Nov 07, 2024

Evolus, Inc. Reports Strong Q3 2024 Growth - TipRanks

Nov 07, 2024

Nov 06, 2024

Evolus Reports Third Quarter 2024 Results - Business Wire

Nov 06, 2024

Nov 05, 2024

Injections For Your Frown Lines Cost Just $49, Thanks To This Membership Club - The Zoe Report

Nov 05, 2024

Nov 04, 2024

Prescription Hair Loss and Hair Removal Drugs Market Projected To Witness Substantial Growth, 2024-2031: - EIN News

Nov 04, 2024

Nov 03, 2024

Evolus receives nod from EU for hyaluronic acid injectables, anticipates US approval - Healio

Nov 03, 2024

Nov 01, 2024

Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 01, 2024

Nov 01, 2024

Evolus to Participate in Stifel 2024 Healthcare Conference - The Bakersfield Californian

Nov 01, 2024

Nov 01, 2024

Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC - MarketBeat

Nov 01, 2024

Nov 01, 2024

Objective long/short (EOLS) Report - Stock Traders Daily

Nov 01, 2024

Oct 31, 2024

Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Marketscreener.com

Oct 31, 2024

Oct 31, 2024

Evolus Gets EU Approval for Treatment of Wrinkles - MarketWatch

Oct 31, 2024

Oct 31, 2024

Evolus gains EU certification for new dermal filler products - Investing.com

Oct 31, 2024

Oct 31, 2024

Evolus gains EU certification for new dermal filler products By Investing.com - Investing.com UK

Oct 31, 2024